Lazard Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Lazard Asset Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,815	Closed	-$123K	–	2638
2022 Q3	$123K	Buy	+1,815	New	+$100K	﹤0.01%	1401
2022 Q2	–	Sell	-2,579	Closed	-$89K	–	2641
2022 Q1	$89K	Hold	2,579	–	–	﹤0.01%	1444
2021 Q4	$75K	Buy	2,579 +617	+31%	+$19.1K	﹤0.01%	1554
2021 Q3	$49K	Buy	+1,962	New	+$57.7K	﹤0.01%	1695
2021 Q1	–	Sell	-1,539	Closed	-$66K	–	2088
2020 Q4	$66K	Buy	+1,539	New	+$75.9K	﹤0.01%	1307

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Lazard Asset Management's GBT Position: Q4 2022 in Review

Lazard Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 1,815 shares — an estimated $123K sold.

Lazard Asset Management first reported a position in GBT in Q4 2020 and held it in 5 quarters. The position peaked at $123K in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Lazard Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Lazard Asset Management sold 1,815 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $123K.
Lazard Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2020 and held it in 5 quarters.
Lazard Asset Management's Global Blood Therapeutics, Inc. position peaked at $123K in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Lazard Asset Management's 13F filing for Q4 2022, filed 15 Feb 2023.